



**UNITED STATES DEPARTMENT OF COMMERCE**  
**United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

07/018,622

07/14/00

HELLSTRAND

K

MAXIM.078A

020995

HM12/0802

KNOBBE MARTENS OLSON & BEAR LLP  
620 NEWPORT CENTER DRIVE  
SIXTEENTH FLOOR  
NEWPORT BEACH CA 92660

EXAMINER

EWOLDT, G

ART UNIT

PAPER NUMBER

1644

DATE MAILED:

08/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

# Office Action Summary

Application No.  
09/616,622

Applicant(s)

Hellstrand et al.

Examiner

G. R. Ewoldt

Art Unit

1644



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_\_
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-34 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claims 1-34 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some\* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

15) ☐ Notice of References Cited (PTO-892)

16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_

18) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_

19) ☐ Notice of Informal Patent Application (PTO-152)

20) ☐ Other:

### DETAILED ACTION

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-3 and 7 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and an adjuvant, classified in Class 424, subclass 185.1+.

II. Claims 1, 2, 4, and 7 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and a vaccine, classified in Class 424, subclass 185.1+.

III. Claims 1, 2, 5, and 7 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and a cytokine, classified in Class 424, subclass 185.1+.

IV. Claims 1, 2, 6, and 7 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and a flavanoid, classified in Class 424, subclass 185.1+.

V. Claims 1 and 8-13 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and a ROM inhibitor, classified in Class 424, subclass 185.1+.

VI. Claims 1 and 8-17 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and a ROM inhibitor and a scavenger of intercellular hydrogen peroxide, classified in Class 424, subclass 185.1+.

VII. Claims 1, 18, 19, and 21 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and an anticancer chemotherapeutic agent, classified in Class 424, subclass 185.1+.

VIII. Claims 1, 18, 20, and 21 drawn to a method of activating and protecting cytotoxic lymphocytes comprising administering to a patient DPI and an antiviral chemotherapeutic agent, classified in Class 424, subclass 185.1+.

IX. Claims 22-24 and 28 drawn to a composition comprising DPI and an adjuvant, classified in Class 424, subclass 185.1+.

X. Claims 22, 23, 25, and 28 drawn to a composition comprising DPI and a vaccine, classified in Class 424, subclass 185.1+.

XI. Claims 22, 23, 26, and 28 drawn to a composition comprising DPI and a cytokine, classified in Class 424, subclass 185.1+.

XII. Claims 22, 23, 27, and 28 drawn to a composition comprising DPI and a flavanoid, classified in Class 424, subclass 185.1+.

XIII. Claims 22 and 29-31 drawn to a composition comprising DPI and a ROM inhibitor, classified in Class 424, subclass 185.1+.

XIV. Claims 22, 32, and 33 drawn to a composition comprising DPI and an anticancer chemotherapeutic agent, classified in Class 424, subclass 185.1+.

XV. Claims 22, 32, and 34 drawn to a composition comprising DPI and an antiviral chemotherapeutic agent, classified in Class 424, subclass 185.1+.

The inventions are distinct, each from the other because:

2. Groups I-VIII are different methods. These inventions comprise different reagents acting through different process steps, i.e., methods of vaccinating versus methods of administering an anticancer therapeutic agent comprise significantly different fields of search. Therefore, the methods are patentably distinct.

3. Inventions IX-XV and I-VIII are related as products and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)).

In the instant case, the products as claimed can be used in materially different processes such as *in vitro* assays.

4. Invention IX-XV are different products. They are distinct because they are structurally and functionally different, i.e., cytokines are chemically and physiologically unrelated to flavanoids. Therefore the Inventions are patentably distinct.

5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their divergent fields of search, restriction for examination purposes as indicated is proper.

6. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

7. Regardless of the Group Applicant should choose to elect, Applicant is further required under 35 U.S.C. § 121 to:

1)

A) Elect a **specific** adjuvant, such as one of those listed in Claim 3 (if Group I or IX is elected),

B) Elect a **specific** vaccine, such as one of those listed in Claim 4 (if Group II or X is elected),

C) Elect a **specific** cytokine, such as one of those listed in Claim 5 (if Group III or XI is elected),

D) Elect a **specific** flavanoid, such as one of those listed in Claim 6 (if Group IV or XII is elected),

E) Elect a **specific** ROM inhibitor, such as one of those listed in Claim 8 (if Group V or XIII is elected),

F) Elect a **specific** ROM inhibitor, such as one of those listed in Claim 8, and a specific scavenger of intercellular hydrogen peroxide, such as one of those listed in Claim 15 (if Group VI is elected),

G) Elect a **specific** anticancer agent, such as one of those listed in Claim 19 (if Group VII or XIV is elected),

H) Elect a **specific** antiviral, such as one of those listed in Claim 20 (if Group VIII or XV is elected),

2) List all Claims readable thereon including those subsequently added. Currently Claims 1 and 22 are generic.


8. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or

admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different adjuvants, vaccines, cytokines, flavanoids, ROM inhibitors, scavengers of intercellular hydrogen peroxide, anticancer agents, and antiviral agents comprise different, unrelated chemical compounds or compositions with different physiological properties and modes of action. For example, different cytokines such as IL-1 and IL-2 are chemically unrelated and function through different receptors on different cell types. Likewise, the different antiviral agents, such as AZT and ganciclovir, are chemically unrelated and function through different pathways on different viruses. Therefore, the species of Groups I-XV are independent and patentable over one another.

9. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D.  
Patent Examiner  
Technology Center 1600  
July 29, 2001

  
Patrick J. Nolan, Ph.D.  
Primary Examiner  
Technology Center 1600